Diabetic kidney disease: Are the reported associations with single-nucleotide polymorphisms disease-specific?

doi:10.4239/wjd.v12.i10.1765

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3999)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

264

WORD

173

HTML

1973

Tables (1-4)

279

Sum=2689

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

369

Download

941

Sum=1310

Oct 15, 2021 (publication date) through Feb 9, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Diabetes. Oct 15, 2021; 12(10): 1765-1777
Published online Oct 15, 2021. doi: 10.4239/wjd.v12.i10.1765

Table 1 Study and control group characteristics

	DKD (n = 117)	NDKD (n = 110)	P value
Age (yr)	68.94 (7.90)	69.87 (10.86)	0.46
Male sex (%)	57 (48.72)	66 (60.00)	0.088
Time-to-dialysis (yr)	5.25 (5.16)	6.23 (6.09)	0.20
Rapid progression of CKD (TTD ≤ 3 mo) (%)	6 (5.13)	6 (5.45)	0.91
Fast progression of CKD (TTD ≤ 1 yr) (%)	29 (24.79)	21 (19.09)	0.30
Slow progression of CKD (TTD > 5 yr) (%)	37 (31.62)	43 (39.09)	0.24
BMI (kg/m²)	30.21 (16.35)	26.01 (5.15)	0.01
Smoking ever (%)	52 (44.44)	58 (53.21)¹	0.19
Preserved diuresis (%)	97 (82.91)	85 (77.27)	0.29
24 h diuresis > 500 mL (%)	49 (41.88)	46(41.82)	0.99
Hypertension (%)	114 (97.44)	102 (92.73)	0.099
ACE-I (%)	50 (43.48)²	39 (39.39)⁴	0.54
ARB (%)	17 (14.78)²	12 (11.76)⁵	0.51
Beta-blockers (%)	89 (76.72)³	91 (89.22)⁵	0.015
Statins (%)	76 (66.09)²	57 (58.16)⁶	0.23

¹Data available for 109 patients.

²Data available for 115 patients.

³Data available for 116 patients.

⁴Data available for 99 patients.

⁵Data available for 102 patients.

⁶Data available for 98 patients.

Significant differences are highlighted in bold. ACE-I: Angiotensin-converting-enzyme inhibitors; ARB: Angiotensin II receptor blockers; BMI: Body mass index; CKD: Chronic kidney disease; DKD: Diabetic kidney disease; NDN: Non-diabetic kidney disease; TTD: Time-to-dialysis (time between the diagnosis of chronic kidney disease and start of hemodialysis).

Citation: Saracyn M, Kisiel B, Franaszczyk M, Brodowska-Kania D, Żmudzki W, Małecki R, Niemczyk L, Dyrla P, Kamiński G, Płoski R, Niemczyk S. Diabetic kidney disease: Are the reported associations with single-nucleotide polymorphisms disease-specific? World J Diabetes 2021; 12(10): 1765-1777
URL: https://www.wjgnet.com/1948-9358/full/v12/i10/1765.htm
DOI: https://dx.doi.org/10.4239/wjd.v12.i10.1765